The Continuing Challenge of Metallo-β-Lactamase Inhibition: Mechanism Matters

Area of Science:

• Microbiology
• Pharmacology
• Drug Discovery

Background:

• Metallo-β-lactamases (MBLs) are enzymes conferring resistance to a majority of clinically used β-lactam antibiotics.
• The global rise of MBL-producing bacteria poses a severe threat to public health, necessitating novel therapeutic strategies.
• Currently, no MBL inhibitors have reached clinical trials, highlighting an urgent unmet medical need.

Purpose of the Study:

• To review the diverse mechanisms employed by metallo-β-lactamase inhibitors.
• To describe methodologies used for characterizing the inhibitory mechanisms of MBLs.
• To provide insights for the rational design of novel MBL inhibitors.

Main Methods:

• Literature review of existing metallo-β-lactamase inhibitors and their mechanisms.
• Analysis of biochemical and biophysical techniques for determining inhibitor-target interactions.
• Survey of structure-activity relationship studies for MBL inhibitors.

Main Results:

• MBL inhibitors function through various mechanisms, including direct zinc chelation and disruption of the catalytic site.
• Different inhibition mechanisms exhibit distinct pharmacological profiles, affecting drug reversibility and selectivity.
• Understanding these mechanisms is crucial for interpreting structure-activity relationships and optimizing inhibitor design.

Conclusions:

• A comprehensive understanding of MBL inhibitor mechanisms is essential for advancing their clinical development.
• Standardized methods for mechanism determination are needed to facilitate comparative studies and guide therapeutic design.
• Further research into novel MBL inhibitor scaffolds and mechanisms holds promise for combating antibiotic resistance.